

ILLINOIS REGION 3 PROTOCOLS

EPINEPHRINE 1:1000 SOLUTION	
CLASS	Sympathomimetic; Catecholamine; bronchodilator
ACTION	<ul style="list-style-type: none"> ▪ Beta-2 receptor agonist promotes bronchodilation ▪ Beta-1 receptor agonist = positive chronotrope (increases heart rate); positive inotrope (increases force of cardiac contraction)
INDICATIONS	<ul style="list-style-type: none"> ▪ Allergic reaction ▪ Anaphylaxis ▪ Asthma ▪ Exacerbation of some forms of COPD
CONTRAINDICATIONS	<ul style="list-style-type: none"> ▪ Patients with underlying cardiovascular disease ▪ Hypertension ▪ Pregnancy (safety in pregnancy and lactation not established) ▪ Patients with tachydysrhythmias
PRECAUTIONS	<ul style="list-style-type: none"> ▪ Protect from light ▪ Monitor vital signs every 5 minutes ▪ Monitor cardiac rhythm closely
SIDE EFFECTS	<ul style="list-style-type: none"> ▪ Tachycardia ▪ Palpitations ▪ Anxiety; restlessness ▪ Tremors ▪ Headache
ROUTE	Subcutaneously
DOSE	0.3 mg SQ
PEDIATRIC DOSE	<ul style="list-style-type: none"> ▪ 0.01 mg/kg up to 0.3 mg ▪ Utilize Broselow tape or pediatric weight based dosing chart to confirm dose ▪ Reference policy PED-10.2
ONSET	5 to 10 minutes
DURATION	20 minutes
STOCK	(3) 1 mg/mL ampules (1) 30 mL multidose vial (1 mg/mL)